Travere Therapeutics Inc (TVTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2015 | 09-2015 | 06-2015 | 03-2015 | 12-2014 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 117,237 | 119,706 | 14,128 | 39,655 | -110,938 |
| Depreciation Amortization | 19,840 | 15,302 | 6,546 | 2,281 | 6,485 |
| Income taxes - deferred | -15,573 | -11,791 | -40,021 | -40,021 | -2,460 |
| Accounts receivable | -4,504 | -5,540 | -3,508 | -203 | -7,959 |
| Accounts payable and accrued liabilities | 3,379 | -1,172 | -3,417 | -2,106 | 20,604 |
| Other Working Capital | -11,372 | -280 | -7,985 | -2,535 | 12,600 |
| Other Operating Activity | -110,396 | -114,062 | 35,681 | -3,665 | 35,818 |
| Operating Cash Flow | $-1,389 | $2,163 | $1,424 | $-6,594 | $-45,850 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -188,553 | -89,816 | 282 | 282 | -3,749 |
| PPE Investments | 148,389 | 148,376 | 3,282 | 3,286 | -663 |
| Net Acquisitions | -33,430 | -33,430 | -33,430 | -33,430 | -29,150 |
| Purchase Of Investment | N/A | N/A | N/A | N/A | -400 |
| Purchase Sale Intangibles | -7,008 | -5,271 | -2,497 | -948 | -3,301 |
| Other Investing Activity | -7,008 | -5,271 | -2,497 | -948 | -3,301 |
| Investing Cash Flow | $-80,602 | $19,859 | $-32,363 | $-30,810 | $-37,263 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | N/A | N/A | 85,290 |
| Debt Repayment | N/A | N/A | N/A | N/A | -31,283 |
| Common Stock Issued | 160,780 | 159,063 | 152,709 | 150,131 | 48,398 |
| Common Stock Repurchased | N/A | N/A | N/A | N/A | -2,257 |
| Other Financing Activity | -59,178 | -58,693 | -12,228 | -10,756 | -4,828 |
| Financing Cash Flow | $101,602 | $100,370 | $140,481 | $139,375 | $95,320 |
| Exchange Rate Effect | -10 | N/A | N/A | N/A | N/A |
| Beginning Cash Position | 18,204 | 18,204 | 18,204 | 18,204 | 5,997 |
| End Cash Position | 37,805 | 140,596 | 127,746 | 120,175 | 18,204 |
| Net Cash Flow | $19,601 | $122,392 | $109,542 | $101,971 | $12,207 |
| Free Cash Flow | |||||
| Operating Cash Flow | -1,389 | 2,163 | 1,424 | -6,594 | -45,850 |
| Capital Expenditure | -22 | -35 | -29 | -25 | -663 |
| Free Cash Flow | -1,411 | 2,128 | 1,395 | -6,619 | -46,513 |